Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics 2024年第一季度GAAP每股收益美元(0.75美元)超過預期(1.09美元),銷售額爲16.77億美元,低於16.88萬美元的預期
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last year.
Plus Therapeutics(納斯達克股票代碼:PSTV)公佈的季度虧損爲每股0.75美元(0.75美元),比分析師普遍預期的1.09美元(1.09美元)高出31.19%。這比去年同期每股虧損2.07美元(2.07)增長了63.77%。該公司公佈的季度銷售額爲16.77億美元,比分析師普遍預期的16.88萬美元低0.62%。這比去年同期的50.6萬美元銷售額增長了231.42%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。